Advertisement

gynäkologie + geburtshilfe

, Volume 23, Supplement 1, pp 36–42 | Cite as

Von der Hysterektomie bis zur Bestrahlung

Leitliniengerechtes Vorgehen beim Endometriumkarzinom

  • Christian Domröse
  • Peter MallmannEmail author
Zertifizierte Fortbildung
  • 251 Downloads

Zusammenfassung

Da Endometriumkarzinome häufig Blutungen verursachen, werden sie in den meisten Fällen in einem frühen Stadium entdeckt. Standard ist eine operative Therapie. Sie wird stadienabhängig durch eine adjuvante Chemotherapie oder Bestrahlung ergänzt.

Literatur

  1. 1.
    Robert-Koch-Institut. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland für 2013/2014. 2017. 11. Ausgabe. Berlin, 2017Google Scholar
  2. 2.
    Morice P et al. Endometrial cancer. Lancet. 2016;387:1094–108CrossRefGoogle Scholar
  3. 3.
    Leitlinienprogramm Onkologie der AWMF, DKG und DKH (Hrsg). S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit. Langversion 1.0 — April 2018; AWMF-Registernummer: 032/034-OLGoogle Scholar
  4. 4.
    Nelson HD et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872–81CrossRefGoogle Scholar
  5. 5.
    Razavi P et al. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:475–83CrossRefGoogle Scholar
  6. 6.
    Lacey JV Jr et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:1724–31CrossRefGoogle Scholar
  7. 7.
    Beral V et al. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543–51CrossRefGoogle Scholar
  8. 8.
    Braithwaite RS et al. (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–47CrossRefGoogle Scholar
  9. 9.
    DeMichele A et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008;26:4151–9CrossRefGoogle Scholar
  10. 10.
    Nelson HD et al. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:604–14CrossRefGoogle Scholar
  11. 11.
    Crosbie EJ et al. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3119–30.CrossRefGoogle Scholar
  12. 12.
    Renehan AG et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78CrossRefGoogle Scholar
  13. 13.
    Reeves KW et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women’s Health Initiative. Gynecol Oncol. 2011;121376–82Google Scholar
  14. 14.
    Zhou B et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121:501–508.e3CrossRefGoogle Scholar
  15. 15.
    Fraser IS et al. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29:383–90CrossRefGoogle Scholar
  16. 16.
    Zaino R et al. Tumours of the uterine Corpus: epithelial Tumours and Precursors. In: WHO Classification of Tumours of Female Reproductive Tract. Volume 6. Lyon: IARC Press; 2014Google Scholar
  17. 17.
    Kurman RJ et al. WHO classification of tumours of female reproductive organs. 4th edition, volume 6. Lyon: IARC-Press; 2014Google Scholar
  18. 18.
    Felix AS et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21:1851–6CrossRefGoogle Scholar
  19. 19.
    Timmermans A et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:160–7CrossRefGoogle Scholar
  20. 20.
    Torres ML et al. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol. 2012;120(5):998–1004.Google Scholar
  21. 21.
    Colombo N et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016;26:2–30CrossRefGoogle Scholar
  22. 22.
    Wittekind C, Meyer J (Hrsg). TNM: Klassifikation maligner Tumoren. 7 Auflage (21. Januar 2010). Weinheim: Wiley-VCH Verlag; 2013Google Scholar
  23. 23.
    Garg G et al. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2013;128:77–82CrossRefGoogle Scholar
  24. 24.
    Strohl AE et al. Surgical wait time: A new health indicator in women with endometrial cancer. Gynecol Oncol. 2016;141:511–5CrossRefGoogle Scholar
  25. 25.
    Martin-Hirsch PP et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev. 2011;(6):CD001040Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe KölnUniversitätsklinikum Köln (AöR)KölnDeutschland

Personalised recommendations